Corporate Support
Sitemap
Singapore

ShareInvestor.com

Mobile Edition
Mode - Streaming
Switch to Static Mode?

Price Highlight

Index Highlight

Chart
STI
3,193.1
-1.6 (-0.05%)

 

  • STI Straits Times Index
    3,193.1
    -1.6 (-0.05%)
     
  • KLCI FTSE Bursa Malaysia KLCI
    1,564.5
    -3.9 (-0.25%)
    Index delayed 15 minutes
  • HSI Hang Seng Index
    26,502.1
    3.7 (0.01%)
    Index delayed 15 minutes
  • SSE SSE Composite Index
    2,909.9
    -2.1 (-0.07%)
    Index delayed 15 minutes
  • N225 Nikkei 225
    23,436.5
    82.1 (0.35%)
    Index delayed 20 minutes
  • JCI Jakarta Composite Index
    6,193.3
    6.4 (0.10%)
    Index delayed 10 minutes
  • KOR KOSPI
    2,088.5
    6.7 (0.32%)
    Index delayed 20 minutes
  • XAO XAO
    6,836.4
    22.9 (0.34%)
     

SGX Market

Bursa Market

HKEx Market

SET Market

IDX Market

ASX Market

NYSE Market

NASDAQ Market

NYSE American Market

  • Volume: 349.1M
  • Value: 397.4M
  • Rise: 105
  • Fall: 126
  • Unch: 595

Intraday Market Ticker Help

Intraday Market Ticker
Time Name Type Price Vol
  • Top Active

  • Top Gainer

  • Top Loser

Top Counters
Name Last Change
Golden Agri-Res0.220-
MDR0.001-0.001
Tritech0.026+0.002
Rex Intl0.170+0.001
YZJ Shipbldg SGD1.100-0.010
JCG Investment0.002-0.001
ComfortDelGro2.430+0.010
SingTel3.420-0.010
CapitaMall Trust2.520+0.010
Ascendas Reit3.030+0.010

World Indices

World Indices
Name Last Change
Nasdaq 8,656.5 +85.8
HSI 26,495.8 -2.5
HSCEI 10,407.8 +0.6
Jakarta 6,193.3 +6.5
Nikkei 225 23,434.7 +80.3
SSE Comp 2,909.4 -2.6
Shanghai A 3,048.5 -2.8
Shanghai B 244.9 +1.5
PSE Comp 0.0
KOSPI 2,087.8 +6.0

Asian Indices delayed. US Indices updated twice daily at 7:30am and 7:30pm.

Fundamental - Factsheet

Help
  • Factsheet

  • Print

CAN FITE BIOPHARMA LTD SPON ADS EA REP 30 ORD SHS(POST REV SPL CAN-FITE BIOPHARMA LTD. SPONSORED ADR
Updated on 06 Dec 2019 (End of trading day)
Last (USD): 3.680 Change: -0.190 High: 3.845 Remarks: -
Change (%): -4.91 Low: 3.450
Open 3.840 Yesterday's Close 3.87
Buy Price - Sell Price -
Buy Volume (share) - Sell Volume (share) -
Cumulative Volume (share) 217,858 Cumulative Value
Click to show Stock Prices chart

Key Statistics

EPS (USD) a -1.97037 Trailing EPS (USD) e -3.39069 NAV (USD) b 2.1227
PE a - Trailing PE f - Price / NAV b 1.7336
Dividend (USD) d - Cash In Hand (USD) g 1.4085 Issued & Paid-up Shares c 3,324,070
Dividend Yield (%) d - Price / Cash In Hand g 2.613 Treasury Shares h -
Beta - 75 Daysi 0.184 R-Squared - 75 Days(%)i 0.11 Market Cap (M) 12.233
Beta - 500 Daysi 2.353 R-Squared - 500 Days (%)i 0.09 Enterprise Value (M) 7.440
Piotroski F Score 2 Exchange Code CANF Par Value ( $ ) n.a.
52 Weeks Volatility (%) 105.88 Free Float (%) -
Sector & Industry Health Technology - Biotechnology
Notes:
  1. Based on latest Full Year results announcement, adjusted for the current number of shares.
  2. Based on latest results announcement (Full Year, Half Year or Interim), adjusted for carrying value of "Other Share Capital", illustrative financial effects of corporate actions (if applicable) and the current number of shares.
  3. Rounded to the nearest thousand. Updated on 07 Jun 2019.Please click here for more information.
  4. Dividend is based on latest Full Year results announcement, adjusted for current number of shares and excludes special dividend.
  5. Summation of the earnings from the latest 4 Quarter (or 2 Half Year) results announcement, adjusted for the current number of shares.
  6. Based on Trailing EPS.
  7. Based on reported cash and cash equivalents at end and extracted from the latest results announcement (Full Year, Half Year or Interim), adjusted for the current number of shares.
  8. Rounded to the nearest thousand. Updated on 17 Sep 2015.
  9. Beta and R-Squared are calculated in relation to the market index using the historical daily closing values of the stock and index as data points.

Peer Comparison

Type Name Market Market Cap (M)a PE b Trailing PE c Price / NAV d Dividend Yield (%)d
Reference CAN FITE BIOPHARMA LTD SPON ADS EA REP 30 ORD SHS(POST REV SPL NYSE American 12.233 - - 1.7336 -
Industry Biotechnology NYSE American 77.243 - - 2.9603 -
Local Peer PFENEX INC NYSE American 249.878 - - 4.4753 -
Local Peer MATINAS BIOPHARMA HOLDINGS INC NYSE American 176.586 - - 5.2004 -
Local Peer NAVIDEA BIOPHARMACEUTICALS INC NYSE American 160.585 - - -210.6383 -
Local Peer NANOVIRICIDES INC NYSE American 146.327 - - 16.0332 -
Local Peer PALATIN TECHNOLOGIES INC NYSE American 121.172 3.387 3.279 1.2605 -
Local Peer LINEAGE CELL THERAPEUTICS INC NYSE American 116.989 - - 0.9986 -
Local Peer 22ND CENTURY GROUP INC NYSE American 100.962 - - 1.8255 -
Local Peer CEL-SCI CORP NYSE American 73.101 - - 63.7622 -
Local Peer SYNTHETIC BIOLOGICS INC NYSE American 52.581 - - 512.5000 -
Local Peer ARMATA PHARMACEUTICALS INC NYSE American 40.034 - - 2.2080 -
Local Peer ISORAY INC NYSE American 33.010 - - 4.7468 -
Local Peer ORAGENICS INC NYSE American 26.943 - - 1.8836 -
Other Local Peers IBIO INC (NYSE American), INDIA GLOBALIZATION CAPITAL INC (NYSE American), ACTINIUM PHARMACEUTICALS INC (NYSE American), NOVABAY PHARMACEUTICALS INC (NYSE American), AIM IMMUNOTECH INC (NYSE American)
Global Peer AMGEN INC NASDAQ 138,902.394 16.548 17.219 12.7119 2.393
Global Peer CSL ASX 127,536.908 47.537 47.537 17.0432 0.944
Global Peer GILEAD SCIENCES INC NASDAQ 84,866.262 15.558 31.514 4.1189 3.444
Global Peer AMGEN-T HKEx 594,184.000 9.032 9.399 6.9364 4.385
Global Peer VERTEX PHARMACEUTICAL NASDAQ 57,408.738 27.385 26.779 10.9279 -
Global Peer BIOGEN INC NASDAQ 54,179.515 12.228 10.041 3.8711 -
Global Peer ILLUMINA INC NASDAQ 47,991.090 58.101 49.323 10.8112 -
Global Peer REGENERON PHARMACEUTICALS INC NASDAQ 40,872.648 16.721 19.062 3.8910 -
Global Peer AGILENT TECHNOLOGIES INC NYSE 25,441.364 80.510 23.755 5.3583 0.745
Global Peer ALEXION PHARMACEUTICAL INC NASDAQ 25,202.832 324.778 17.141 2.4310 -
Other Global Peers INCYTE CORPORATION (NASDAQ), SEATTLE GENETICS INC (NASDAQ), SINO BIOPHARM (HKEx), WUXI BIO (HKEx), BIOMARIN PHARMACEUTICAL (NASDAQ), GALAPAGOS NV SPON ADR REPR 1 ORD SHS (NASDAQ), ALNYLAM PHARMACEUTICALS INC (NASDAQ), EXACT SCIENCES CORP (NASDAQ), BEIGENE (HKEx), BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS (NASDAQ), NEUROCRINE BIOSCIENCES INC (NASDAQ), IONIS PHARMACEUTICALS INC (NASDAQ), BIO-TECHNE CORP (NASDAQ), SAREPTA THERAPEUTICS INC (NASDAQ), ACADIA PHARMACEUTICALS INC (NASDAQ), ARROWHEAD PHARMACEUTICALS INC (NASDAQ), MODERNA INC (NASDAQ), 10X GENOMICS INC (NASDAQ), BIONTECH SE SPON ADS EACH REP 1 ORD SHS (NASDAQ), EXELIXIS INC (NASDAQ), ASCENDIS PHARMA A/S SPON ADR EACH REP 1 ORD SHS (NASDAQ), GLOBAL BLOOD THERAPEUTICS INC (NASDAQ), GENSCRIPT BIO (HKEx), REPLIGEN CORP (NASDAQ), CHINA BIOLOGIC PRODUCTS HLDGS INC (NASDAQ), BLUEBIRD BIO INC (NASDAQ), Lonza (SGX), CRISPR THERAPEUTICS AG (NASDAQ), MORPHOSYS SPON ADS EACH REP 0.25 ORD SHS (NASDAQ), SPARK THERAPEUTICS INC (NASDAQ), FIBROGEN INC (NASDAQ), MIRATI THERAPEUTICS INC (NASDAQ), IMMUNOMEDICS INC (NASDAQ), BLUEPRINT MEDICINES CORP (NASDAQ), ALLOGENE THERAPEUTICS INC (NASDAQ), 3SBIO (HKEx), NEKTAR THERAPEUTICS (NASDAQ), ALKERMES PLC (NASDAQ), IOVANCE BIOTHERAPEUTICS INC (NASDAQ), PTC THERAPEUTICS INC (NASDAQ), NATERA INC (NASDAQ), UNIQURE N.V. (NASDAQ), HALOZYME THERAPEUTICS INC (NASDAQ), AGIOS PHARMACEUTICALS INC (NASDAQ), ZAI LAB LIMITED ADS EACH REP 1 ORD SHS (NASDAQ), AUDENTES THERAPEUTICS INC (NASDAQ), EMERGENT BIOSOLUTIONS INC (NYSE), DECIPHERA PHARMACEUTICALS INC (NASDAQ), ACCELERON PHARMA (NASDAQ), AMICUS THERAPEUTICS INC (NASDAQ), ULTRAGENYX PHARMACEUTICAL INC (NASDAQ), ARENA PHARMACEUTICALS INC (NASDAQ), KODIAK SCIENCES INC (NASDAQ), XENCOR INC (NASDAQ), HERON THERAPEUTICS INC (NASDAQ), EIDOS THERAPEUTICS INC (NASDAQ), INSMED INC (NASDAQ), MYRIAD GENETICS INC (NASDAQ), LIGAND PHARMACEUTICAL INC (NASDAQ), AIMMUNE THERAPEUTICS INC (NASDAQ), CHEMOCENTRYX INC (NASDAQ), DICERNA PHARMACEUTICALS INC. (NASDAQ), MOMENTA PHARMACEUTICALS INC (NASDAQ), DENALI THERAPEUTICS INC (NASDAQ), HAOHAI BIOTEC (HKEx), EPIZYME INC (NASDAQ), REGENXBIO INC (NASDAQ), EDITAS MEDICINE INC (NASDAQ), MYOVANT SCIENCES LTD (NYSE), ARVINAS INC (NASDAQ), AURINIA PHARMACEUTICALS INC (NASDAQ), VERACYTE INC (NASDAQ), VIELA BIO INC (NASDAQ), VIR BIOTECHNOLOGY INC (NASDAQ), ESPERION THERAPEUTICS INC (NASDAQ), ALECTOR INC (NASDAQ), SANGAMO THERAPEUTICS INC (NASDAQ), NEXTCURE INC (NASDAQ), COHERUS BIOSCIENCES INC (NASDAQ), ENANTA PHARMACEUTICALS INC (NASDAQ), ZEALAND PHARMA AS SPON ADR EACH REP 1 ORD SHS (NASDAQ), NGM BIOPHARMACEUTICALS INC (NASDAQ), ROCKET PHARMACEUTICALS INC (NASDAQ), WAVE LIFE SCIENCES LTD (NASDAQ), RHYTHM PHARMACEUTICALS INC (NASDAQ), OPKO HEALTH INC (NASDAQ), FRONTAGE (HKEx), FATE THERAPEUTICS (NASDAQ), SPECTRUM PHARMACEUTICALS INC (NASDAQ), KARYOPHARM THERAPEUTICS INC (NASDAQ), RADIUS HEALTH INC (NASDAQ), PRECISION BIOSCIENCES INC (NASDAQ), STOKE THERAPEUTICS INC (NASDAQ), NANOSTRING TECHNOLOGIES INC (NASDAQ), LUMINEX CORP(DEL) (NASDAQ), ZIOPHARM ONCOLOGY INC (NASDAQ), CKLIFE SCIENCES (HKEx), VANDA PHARMACE INC (NASDAQ), VIVA BIOTECH (HKEx), AVITA MEDICAL LTD SPON ADS EACH REP 20 ORD SHS (NASDAQ), ASCENTAGE-B (HKEx), AVITA MEDICAL LTD (ASX), INTREXON CORP (NASDAQ), ACHILLION PHARMACEUTICALS INC (NASDAQ), RUBIUS THERAPEUTICS INC (NASDAQ), INTELLIA THERAPEUTICS INC (NASDAQ), TWIST BIOSCIENCE CORPORATION (NASDAQ), SYNTHORX INC (NASDAQ), POLYNOVO LIMITED (ASX), HOMOLOGY MEDICINES INC (NASDAQ), CARA THERAPEUTICS INC (NASDAQ), MEIRAGTX HOLDINGS PLC (NASDAQ), PACIFIC BIOSCIENCES CALIFORNIA INC (NASDAQ), CORTEXYME INC (NASDAQ), ATARA BIOTHERAPEUTICS INC (NASDAQ), FLEXION THERAPEUTICS INC (NASDAQ), DBV TECHNOLOGIES SPON ADR EACH REPR 0.5 ORD (NASDAQ), ADVERUM BIOTECHNOLOGIES INC (NASDAQ), MESOBLAST LTD SPON ADR EACH REP 5 SHS (NASDAQ), TG THERAPEUTICS INC (NASDAQ), KURA ONCOLOGY INC (NASDAQ), AKEBIA THERAPEUTICS INC (NASDAQ), MESOBLAST LTD (ASX), UROGEN PHARMA LTD (NASDAQ), AUTOLUS THERAPEUTICS PLC SPON ADS EA REP 1 ORD SHS (NASDAQ), OMEROS CORP (NASDAQ), KADMON HLDGS INC (NYSE), CELLECTIS ADS EACH REPR 1 ORD SPON (NASDAQ), GENFIT SPON ADS EACH REP 1 ORD SHS (NASDAQ), TRANSLATE BIO INC (NASDAQ), SORRENTO THERAPEUTICS INC (NASDAQ), IMMUNOGEN INC (NASDAQ), RETROPHIN INC (NASDAQ), AVROBIO INC (NASDAQ), INTRA-CELLUAR THERAPIES INC (NASDAQ), CYTOKINETICS INC (NASDAQ), AGENUS INC (NASDAQ), MOLECULAR TEMPLATES INC (NASDAQ), VIKING THERAPEUTICS INC (NASDAQ), PREVAIL THERAPEUTICS INC (NASDAQ), CLOVIS ONCOLOGY INC (NASDAQ), RAPT THERAPEUTICS INC (NASDAQ), SINOMAB BIO-B (HKEx), VOYAGER THERAPEUTICS INC (NASDAQ), MAGENTA THERAPEUTICS INC (NASDAQ), LEXICON PHARMACEUTICALS INC (NASDAQ), STEMLINE THERAPEUTICS INC (NASDAQ), PROTHENA CORP PLC (NASDAQ), MORPHIC HOLDING INC (NASDAQ), REPLIMUNE GROUP INC (NASDAQ), ASCLETIS-B (HKEx), INNATE PHARMA SPON ADS EACH REP 1 ORD SHS (NASDAQ), DYNAVAX TECHNOLOGIES CORP (NASDAQ), FREQUENCY THERAPEUTICS INC (NASDAQ), MACROGENICS INC (NASDAQ), HARPOON THERAPEUTICS INC (NASDAQ), SINOVAC BIOTECH LTD (NASDAQ), MERUS B V (NASDAQ), XBIOTECH INC (NASDAQ), PROGENICS PHARMACEUTICALS INC (NASDAQ), DERMIRA INC (NASDAQ), ESSEX BIO-TECH (HKEx), STEALTH BIOTHERAPEUTICS CORP SPON ADS EACH REP 12 ORD SHS (NASDAQ), BIOCRYST PHARMACEUTICALS INC (NASDAQ), ARDELYX INC (NASDAQ), PROQR THERAPEUTICS N V (NASDAQ), BELLUS HEALTH INC (NASDAQ), MERIDIAN BIOSCIENCE INC COM (NASDAQ), ANAPTYSBIO INC (NASDAQ), RECRO PHARMA INC (NASDAQ), RIGEL PHARMACEUTICALS INC (NASDAQ), XENON PHARMACEUTICALS INC (NASDAQ), APPLIED THERAPEUTICS INC (NASDAQ), ARCUS BIOSCIENCES INC (NYSE), MEDICINOVA INC (NASDAQ), CELLULAR BIOMEDICINE GROUP INC (NASDAQ), PDL BIOPHARMA INC (NASDAQ), COMPUGEN (NASDAQ), CORBUS PHARMACEUTICALS HOLDINGS IN (NASDAQ), AVID BIOSERVICES INC (NASDAQ), EIGER BIOPHARMACEUTICALS INC (NASDAQ), STARPHARMA HOLDINGS LIMITED (ASX), EVOFEM BIOSCIENCES INC (NASDAQ), UNITY BIOTECHNOLOGY INC (NASDAQ), CASI PHARMACEUTICALS INC (NASDAQ), PUMA BIOTECHNOLOGY INC (NASDAQ), GERON CORP (NASDAQ), KAMADA (NASDAQ), PERSONALIS INC (NASDAQ), LEE'S PHARM (HKEx), TELIX PHARMACEUTIC (ASX), CYTOMX THERAPEUTICS INC (NASDAQ), CUE BIOPHARMA INC (NASDAQ), NEPTUNE WELLNESS SOLUTIONS INC (NASDAQ), GLYCOMIMETICS INC (NASDAQ), JOUNCE THERAPEUTICS INC (NASDAQ), SERES THERAPEUTICS (NASDAQ), ADMA BIOLOGICS INC (NASDAQ), SCHOLAR ROCK HOLDING CORPORATION (NASDAQ), CALITHERA BIOSCIENCES INC (NASDAQ), MANNKIND CORPORATION (NASDAQ), NEXT SCIENCE LTD (ASX), NEUROINSIGHTS NEUROTECH (NASDAQ), SYNDAX PHARMACEUTICALS INC (NASDAQ), REDHILL BIOPHARMA LTD SPON ADS EA REPR 10 ORD ILS0.00 (NASDAQ), DPHARMA (Bursa), BIOFRONTERA AG SPON ADS EACH REP TWO ORD SHS (NASDAQ), NUCANA PLC SPON ADR EACH REP 1 ORD SHS (NASDAQ), XOMA CORP (NASDAQ), CHIASMA INC (NASDAQ), SOLID BIOSCIENCES INC (NASDAQ), ATHERSYS INC (NASDAQ), ELOXX PHARMACEUTICALS INC (NASDAQ), MERSANA THERAPEUTICS INC (NASDAQ), PROTAGONIST THERAPEUTICS INC (NASDAQ), SYROS PHARMACEUTICALS INC (NASDAQ), PIERIS PHARMACEUTICALS INC (NASDAQ), IVERIC BIO INC (NASDAQ), PROTEOSTASIS THERAPEUTICS INC (NASDAQ), TAIWAN LIPOSOME COMPANY LTD SPON ADS EACH REP 2 ORD SHS (NASDAQ), CABALETTA BIO INC (NASDAQ), CONCERT PHARMACEUTICALS INC (NASDAQ), AFFIMED N V (NASDAQ), X4 PHARMACEUTICALS INC (NASDAQ), BBI LIFE SCI (HKEx), GALECTIN THERAPEUTICS INC (NASDAQ), DYADIC INTERNATIONAL INC (NASDAQ), ARAVIVE INC (NASDAQ), NEUREN PHARMACEUTICALS LTD (ASX), NANTKWEST INC (NASDAQ), VBI VACCINES INC CDA (NASDAQ), CHIMERIX INC (NASDAQ), BICYCLE THERAPEUTICS PLC SPON ADS EACH REP 1 ORD SHS (NASDAQ), IMV INC (NASDAQ), APTOSE BIOSCIENCES INC (NASDAQ), FIVE PRIME THERAPEUTICS (NASDAQ), FORTRESS BIOTECH INC (NASDAQ), NABRIVA THERAPEUTICS PLC (NASDAQ), EDAP TMS S.A. SPON ADR EACH REPR 1 ORD SHARE (NASDAQ), ANAVEX LIFE SCIENCES CORPORATION (NASDAQ), ALDEYRA THERAPEUTICS (NASDAQ), LIMINAL BIOSCIENCES INC (NASDAQ), RESAPP HEALTH LIMITED (ASX), ARBUTUS BIOPHARMA CORP (NASDAQ), ENZO BIOCHEM INC (NYSE), UNI-BIO GROUP (HKEx), FENNEC PHARMACEUTICALS INC (NASDAQ), SESEN BIO INC (NASDAQ), AVEO PHARMACEUTICALS INC (NASDAQ), CYMABAY THERAPEUTICS INC (NASDAQ), BIOXCEL THERAPEUTICS INC (NASDAQ), ADAPTIMMUNE THERAPEUTICS PLC ADS EACH REPR 6 SHS (SPONS) (NASDAQ), NOVAVAX INC (NASDAQ), PYC THERAPEUTICS LIMITED (ASX), HARVARD BIOSCIENCE INC (NASDAQ), AXOVANT GENE THERAPIES LTD (NASDAQ), AVALON GLOBOCARE CORP (NASDAQ), PARATEK PHARMACEUTICALS INC (NASDAQ), VERASTEM INC (NASDAQ), STRONGBRIDGE BIOPHARMA PLC (NASDAQ), IMUGENE LIMITED (ASX), ADURO BIOTECH INC (NASDAQ), CHAMPIONS ONCOLOGY INC (NASDAQ), VTV THERAPEUTICS INC (NASDAQ), BRAINSTROM CELL THERAPEUTICS (NASDAQ), LA JOLLA PHARMACEUTICAL CO (NASDAQ), CIDARA THERAPEUTICS INC (NASDAQ), AXCELLA HEALTH INC (NASDAQ), INFLARX N V (NASDAQ), ACORDA THERAPEUTICS INC (NASDAQ), ERYTECH PHARMA SPON ADR EACH REPR 1 ORD (NASDAQ), CYNATA THERAPEUTICS LTD (ASX), OTONOMY INC (NASDAQ), ASLAN PHARMACEUTICALS LIMITED ADS EACH REP 5 ORD SHS (NASDAQ), ANIXA BIOSCIENCES INC (NASDAQ), SYNLOGIC INC (NASDAQ), TIZIANA LIFE SCIENCES PLC SPON ADS EACH REPR 10 ORD SHS (NASDAQ), SELECTA BIOSCIENCES INC (NASDAQ), ONCOSIL MEDICAL LIMITED (ASX), VERMILLION INC (NASDAQ), VACCINEX INC (NASDAQ), INFINITY PHARMACEUTICALS INC (NASDAQ), COHBAR INC (NASDAQ), CATABASIS PHARMACEUTICALS INC (NASDAQ), EQUILLIUM INC (NASDAQ), CORREVIO PHARMA CORP (NASDAQ), TREVENA INC (NASDAQ), ENTASIS THERAPEUTICS HLDGS INC (NASDAQ), IMMUTEP LTD SPON ADS EACH REP 10 ORD SHS (NASDAQ), ORGANOVO HLDGS INC (NASDAQ), IMMUTEP LTD (ASX), CATALYST BIOSCIENCES INC (NASDAQ), SURFACE ONCOLOGY INC (NASDAQ), PLURISTEM THERAPEUTICS INC (NASDAQ), T2 BIOSYSTEMS INC (NASDAQ), ALPINE IMMUNE SCIENCES INC (NASDAQ), MERRIMACK PHARMACEUTICALS INC (NASDAQ), NEWLINK GENETICS CORP (NASDAQ), GENOCEA BIOSCIENCES INC (NASDAQ), INMUNE BIO INC (NASDAQ), OPIANT PHARMACEUTICALS INC (NASDAQ), ORTHOCELL LIMITED (ASX), APPLIED GENETIC TECHNOLOGIES CORP (NASDAQ), IDERA PHARMACEUTICALS INC (NASDAQ), CURIS INC (NASDAQ), KEZAR LIFE SCIENCES INC (NASDAQ), SUMMIT THERAPEUTICS PLC ADS EACH REPR 5 ORD (NASDAQ), ITERUM THERAPEUTICS PLC (NASDAQ), AQUABOUNTY TECHNOLOGIES INC (NASDAQ), RESTORBIO INC (NASDAQ), SAVARA INC (NASDAQ), VASCULAR BIOGENICS LTD (NASDAQ), ORGENESIS INC (NASDAQ), CT ENTERPRISE (HKEx), PORT (SET), MEREO BIOPHARMA GROUP PLC SPON ADS EACH REP 5 ORD SHS (NASDAQ), CELLDEX THERAPEUTICS INC (NASDAQ), BELLICUM PHARMACEUTICALS (NASDAQ), FORWARD PHARMA AS SPON ADS EACH REP 14 ORD SHS (NASDAQ), ALIMERA SCIENCES INC (NASDAQ), SIERRA ONCOLOGY INC (NASDAQ), HTG MOLECULAR DIAGNOSTICS INC (NASDAQ), BIONOMICS LTD (ASX), SUNESIS PHARMACEUTICALS INC (NASDAQ), BIOSINO BIO-TEC (HKEx), ACTINOGEN MEDICAL LTD (ASX), DIAMEDICA THERAPEUTICS INC (NASDAQ), EVOGENE LTD (NASDAQ), KAZIA THERAPEUTICS LIMITED (ASX), OUTLOOK THERAPEUTICS INC (NASDAQ), KAZIA THERAPEUTICS LIMITED SPON ADR EACH REP 10 ORD SHS (NASDAQ), ONCOLYTICS BIOTECH INC (NASDAQ), ZAFGEN INC (NASDAQ), BIONANO GENOMICS INC (NASDAQ), INVEX THERAPEUTICS LTD NPV (ASX), FIBROCELL SCIENCE INC (NASDAQ), REGENT PACIFIC (HKEx), SEELOS THERAPEUTICS INC (NASDAQ), NEON THERAPEUTICS INC (NASDAQ), APTEVO THERAPEUTICS INC (NASDAQ), NOVITA HEALTHCARE LTD (ASX), PRESCIENT THERAPEUTICS LIMITED (ASX), BIOCARDIA INC (NASDAQ), INNOVATE BIOPHARMACEUTICALS INC (NASDAQ), MEMPHASYS LTD (ASX), CONTRAFECT CORP (NASDAQ), BIOTRON (ASX), SOLIGENIX INC (NASDAQ), RHINOMED LIMITED (ASX), BIO-PATH HOLDINGS INC (NASDAQ), MICROBOT MEDICAL INC (NASDAQ), EXTRAWELL PHAR (HKEx), UNUM THERAPEUTICS INC (NASDAQ), AZURRX BIOPHARMA INC (NASDAQ), SELLAS LIFE SCIENCES GROUP INC (NASDAQ), LEAP THERAPEUTICS INC (NASDAQ), PROTEOMICS INTL LABORATORIES LTD (ASX), ADVAXIS INC (NASDAQ), VISTAGEN THERAPEUTICS INC (NASDAQ), AEVI GENOMIC MEDIC (NASDAQ), MIRAGEN THERAPEUTICS INC (NASDAQ), ANTEOTECH LIMITED (ASX), REGENEUS LTD (ASX), CELLECTAR BIOSCIENCES INC (NASDAQ), IMMURON LIMITED SPON ADR EACH REPR 40 ORD SHS (NASDAQ), IMMURON LIMITED (ASX), PULMATRIX INCORPORATED (NASDAQ), ATYR PHARMA INC (NASDAQ), CO DIAGNOSTICS INC (NASDAQ), AETERNA ZENTARIS INC (NASDAQ), SENESTECH INC (NASDAQ), CELLMID LIMITED (ASX), PATRYS LIMITED (ASX), DARE BIOSCIENCE INC (NASDAQ), HEAT BIOLOGICS INC (NASDAQ), TOCAGEN INC (NASDAQ), VAXART INC (NASDAQ), PRECIPIO INC (NASDAQ), OCUGEN INC (NASDAQ), CONTANGO ASSET MANAGEMENT LIMITED (ASX), Suntar Eco-City^ (SGX), MIDATECH PHARMA PLC SPON ADS EACH REP 20 ORD SHS(R/S) (NASDAQ), ALTERITY THERAPEUTICS LIMITED (ASX), ALTERITY THERAPEUTICS LIMITED SPON ADS EA REPR 60 ORD SHS (NASDAQ), GENETIC TECHNOLOGIES (ASX), BIOCEPT INC (NASDAQ), SOPHIRIS BIO INC (NASDAQ), CONATUS PHARMACEUTICALS INC (NASDAQ), HOLISTA COLLTECH LIMITED (ASX), ANCHIANO THERAPEUTICS LTD SPON ADS EACH REP 5 ORD SHS (NASDAQ), ADALTA LTD (ASX), NEUROSCIENTIFIC BIOPHARMA LTD (ASX), TROVAGENE INC (NASDAQ), CYCLACEL PHARMA IN (NASDAQ), CCP TECHNOLOGIES LTD (ASX), TRACON PHARMACEUTICALS INC (NASDAQ), GENETIC TECHNOLOGIES SPON ADS EA REP 600 ORD SHS(R/S) (NASDAQ), BENITEC BIOPHARMA LTD (ASX), ARCA BIOPHARMA INC (NASDAQ), MEGASUN (Bursa), TRILLIUM THERAPEUTICS INC (NASDAQ), MEDIBIO LIMITED (ASX), BENITEC BIOPHARMA LTD SPON ADS EA REPR 200 ORD SHS(POST SPLIT) (NASDAQ), MGRC (Bursa), AUSTRALIAN PRIMARY HEMP LTD (ASX), HAO WEN HLDGS (HKEx), XENETIC BIOSCIENCES INC (NASDAQ), PLUS THERAPEUTICS INC (NASDAQ), ACHIEVE LIFE SCIENCE INC (NASDAQ), CLEVELAND BIOLABS INC (NASDAQ), REXAHN PHARMACEUTICALS INC (NASDAQ), ENDRA LIFE SCIENCES INC (NASDAQ), ANATARA LIFESCIENCES LTD (ASX), XTL BIOPHARMACEUTICALS LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), TBG DIAGNOSTICS LTD (ASX), LIVING CELL TECHNOLOGIES (ASX), BIOXYNE LIMITED (ASX), OPGEN INC (NASDAQ), CELLECT BIOTECHNOLOGY LTD SPON ADS EACH REP 100 ORD SHS(POST SPLT) (NASDAQ), SIENNA CANCER DIAGNOSTICS LTD (ASX), PROTEON THERAPEUTICS INC (NASDAQ), CAPRICOR THERAPEUTICS INC (NASDAQ), THERAPIX BIOSCIENCES LTD SPON ADR EACH REP 40 ORD (POST SPLIT) (NASDAQ), PHIO PHARMACEUTICALS CORP (NASDAQ), QT Vascular (SGX), DIFFUSION PHARMACEUTICALS INC (NASDAQ), AVECHO BIOTECHNOLOGY LTD (ASX), SENECA BIOPHARMA INC (NASDAQ), AURIS MEDICAL HOLDING LTD (NASDAQ), SPHERIX INC (NASDAQ), BPH ENERGY LIMITED (ASX), ONCONOVA THERAPEUTICS INC (NASDAQ), AMPLIA THERAPEUTICS LTD (ASX), NANOLLOSE LTD (ASX), INVIVO THERAPEUTICS HOLDING CORP (NASDAQ), FACTOR THERAPEUTICS LIMITED (ASX), MOTIF BIO PLC ADR EACH REPR 20 SHS SPON (NASDAQ)
Notes:
  1. For companies, Market Cap is based on the trading currency of the company. Industry/Index Market Cap is the average market cap for that industry/index.
  2. Industry/Index PE is calculated using (Total Market Cap/Total Earnings) of all companies in the industry/index.
  3. Industry/Index Price/NAV is calculated using (Total Market Cap/Total Shareholders' Equity) of all companies in the industry/index.
  4. Industry/Index Dividend Yield is calculated using (Total Gross Dividend/Total Market Cap) of all companies in the industry/index.
  5. For Industry/Index calculation, data for foreign currency denominated companies will be converted to the main market currency using the latest exchange rate.
  6. Industry/Index/Peers data is updated daily.
  7. Peers are sorted by market capitalisation and only details for the top 10 will be shown.

Total Shareholder Return

PeriodDividend ReceivedCapital AppreciationTotal Shareholder Return
Short Term Return 5 Days --0.520
-12.38 %
10 Days -+1.210
+48.99 %
20 Days -+1.200
+48.39 %
Medium Term Return 3 Months -+1.290
+53.97 %
6 Months -+0.800
+27.78 %
1 Year --15.525
-80.84 %
Long Term Return 2 Years --16.270
-81.55 %
3 Years --27.970
-88.37 %
5 Years --49.120
-93.03 %
Annualised Return Annualised --
-41.30 %
Notes:
  1. Total Shareholder Return (TSR) combines share price appreciation and dividends paid to show the total return to the shareholder expressed as a percentage.
  2. Script dividends are ignored in this calculation.

Price Movements

1 Year Range 1.900 - 24.300 Change From 1 Year Low +1.780 % Change From 1 Year Low (%) +93.68
Change From 1 Year High -20.620 % Change From 1 Year High (%) -84.86
2 Years Range 1.900 - 41.250 Change From 2 Years Low +1.780 % Change From 2 Years Low (%) +93.68
Change From 2 Years High -37.570 % Change From 2 Years High (%) -91.08
5 Years Range 1.900 - 117.750 Change From 5 Years Low +1.780 % Change From 5 Years Low (%) +93.68
Change From 5 Years High -114.070 % Change From 5 Years High (%) -96.87
Notes:
  1. Price movements are based on adjusted historical data.

Company Background

Can-Fite BioPharma Ltd. operates as a clinical-stage biopharmaceutical company, which focuses on developing orally bioavailable small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological and ophthalmic diseases. Its products include pipeline drugs such as CF101, CF102 and CF602. The company offers drugs for the treatment of Psoriasis, Rheumatic Arthritis, Glaucoma, Uveitis, Crohn's disease, Osteoathritis, Hepatitis C, and Liver Cancer. Can-Fite BioPharma was founded by Pnina Fishman and Ilan Cohn on September 11, 1994 and is headquartered in Petach Tikva, Israel.

Historical Price Data

Date Open High Low Close Volume VWAP
06 Dec 2019 3.840 3.845 3.450 3.680 217,858 -
05 Dec 2019 4.360 4.440 3.700 3.870 408,894 -
04 Dec 2019 4.030 4.490 3.923 4.400 899,237 -
03 Dec 2019 4.170 4.700 3.700 3.770 1,153,961 -
02 Dec 2019 3.430 4.950 3.140 4.200 2,818,217 -
29 Nov 2019 3.780 3.820 3.060 3.540 8,114,054 -
27 Nov 2019 2.520 2.600 2.510 2.570 37,434 -
26 Nov 2019 2.550 2.550 2.454 2.530 38,245 -
25 Nov 2019 2.720 2.730 2.470 2.470 125,570 -
22 Nov 2019 2.610 2.724 2.500 2.652 228,236 -
21 Nov 2019 2.510 2.680 2.452 2.600 143,939 -
20 Nov 2019 2.500 2.508 2.390 2.480 72,524 -
19 Nov 2019 2.560 2.610 2.350 2.410 426,717 -
18 Nov 2019 2.440 2.450 2.305 2.360 105,690 -
15 Nov 2019 2.320 2.450 2.320 2.440 33,168 -
14 Nov 2019 2.410 2.410 2.290 2.390 23,753 -
13 Nov 2019 2.380 2.383 2.280 2.370 41,554 -
12 Nov 2019 2.540 2.540 2.380 2.420 49,085 -
11 Nov 2019 2.450 2.480 2.390 2.480 127,744 -
08 Nov 2019 2.290 2.380 2.270 2.380 23,423 -
07 Nov 2019 2.500 2.500 2.310 2.320 43,914 -
06 Nov 2019 2.390 2.530 2.240 2.510 213,850 -
Summary
Current 2 Weeks
(22 Nov 2019 to 06 Dec 2019)
2.610 4.950 2.455 3.680 14,041,706 -
Previous 2 Weeks
(08 Nov 2019 to 21 Nov 2019)
2.290 4.950 2.270 2.600 1,047,597 -
4 Weeks from
(11 Oct 2019 to 07 Nov 2019)
2.150 4.950 2.120 2.320 10,938,008 -
View All Historical Data

More Information Available

More information is available to our subscribers, including:

  • Market Moving News from Dow Jones Newswires
  • Consensus Estimates
  • Dividend/Distribution History
  • Financial Summary with Financial Period Comparison
  • Comprehensive Financial Ratios(ROA, ROE, Price/Revenue, Net Earnings Margin, Current Ratio, Debt to Equity Ratio etc)
  • Events Calendar for Results Announcements, Ex-Dates etc
  • Insider Buying and Selling Report

If you are an existing subscriber, please login. If not, read up on what you are missing out in our Help Centre and join us as a subscriber.

Disclaimer:

While reasonable efforts have been taken to ensure that the calculations performed by the features of this site are reliable, the features are provided on the basis that:-

  1. no liability is accepted for any errors or inaccuracies resulting from your use of these features;
  2. many of the data inputs (including share prices) are obtained from third party sources for which we assume no responsibility.